CD66b as a prognostic and predictive biomarker in patients with non-small cell lung cancer treated with checkpoint blockade immunotherapy Editorial

   

Authors:	Jain, S.; Ma, K.; Morris, L. G. T.
Title:	CD66b as a prognostic and predictive biomarker in patients with non-small cell lung cancer treated with checkpoint blockade immunotherapy
Keywords:	cancer survival; treatment response; unclassified drug; overall survival; histopathology; cancer recurrence; note; cancer patient; disease free survival; cancer staging; cd8+ t lymphocyte; lymphocyte proliferation; tumor associated leukocyte; cancer immunotherapy; progression free survival; tumor antigen; tumor marker; cancer resistance; regulatory t lymphocyte; neutrophil; biomarker; cytotoxic t lymphocyte; tumor immunity; lung carcinogenesis; disease specific survival; predictive value; antibody dependent cellular cytotoxicity; programmed death 1 ligand 1; programmed death 1 receptor; non small cell lung cancer; tumor microenvironment; clinical outcome; survival prediction; lymphocyte antigen; immune checkpoint inhibitor; cancer prognosis; human; polymorphonuclear cell; non-small cell lung cancer (nsclc); patient history of therapy; tumor associated neutrophil; myeloid-derived suppressor cell; digital spatial profiling; cd66b; tumor associated neutrophils; cd66b antigen
Journal Title:	Translational Cancer Research
Volume:	12
Issue:	2
ISSN:	2218-676X
Publisher:	Pioneer Bioscience Publishing Company
Date Published:	2023-02-28
Start Page:	447
End Page:	451
Language:	English
DOI:	10.21037/tcr-22-2880
PROVIDER:	scopus
PMCID:	PMC10007870
PUBMED:	36915573
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85154609737&doi=10.21037%2ftcr-22-2880&partnerID=40&md5=62d71857f3745af4f5f0d7f072eabf4b
Notes:	Note -- Kevin Ma is a medical student that is incorrectly affiliated with MSK on the original publication -- Export Date: 1 June 2023 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/206586